On φ-pseudo symmetric LP-Sasakian manifolds with respect to quarter-symmetric non-metric connections

The object of the present paper is to study φ-pseudo symmetric and φ-pseudo Ricci symmetric LP-Sasakian manifolds with respect to Levi–Civita connections and quarter-symmetric non-metric connections. We obtain a necessary and sufficient condition for a φ-pseudo symmetric LP-Sasakian manifold with respect to a quarter symmetric non-metric connection to be φ-pseudo symmetric LP-Sasakian manifold with respect to a Levi–Civita connection

Conformal mappings of mixed generalized quasi-Einstein manifolds admitting special vector fields

It is known that Einstein manifolds form a natural subclass of the class of quasi-Einstein manifolds and plays an important role in geometry as well as in general theory of relativity. In this work, we investigate conformal mapping of mixed generalized quasi- Einstein manifolds, considering a conformal mapping between two mixed generalized quasi- Einstein manifolds Vn and V ̅n. We also find some properties of this transformation from Vn to V ̅n and some theorems are proved. Considering this mapping, we peruse some properties of these manifolds. Later, we also study some special vector fields under these mapping on this manifolds and some theorems about them are proved.Gobierno de la India. Primer autor apoyado por DST / INSPIRE Fellowship / 2013/1041peerReviewe

Renal safety profile of di-peptidyl-peptidase inhibitors: a review of available literature

Diabetic Nephropathy has become the single most import cause of End Stage Renal Disease (ESRD). Various strategies to limit or slow the progress the Diabetic nephropathy are suggested by the guidelines and evidences. By maintaining strict glycemic control the progression of diabetic nephropathy can be altered. Glycemic control in diabetic patients with nephropathy is complex as falling eGFR renders many ant diabetic medications contraindicated while others are needed to be done in low dose. The intent of this review article is to collate the available evidences for renal safety with one such anti diabetic class of medication, dipeptidyl peptidase 4 inhibitor and evaluate the guideline based antidiabetic treatment in Type 2 Diabetes Mellitus patients with renal insufficiency.